Core Insights - Senti Biosciences, Inc. presented positive Phase 1 data for its lead program SENTI-202 at the AACR Annual Meeting, indicating potential as a treatment for Acute Myeloid Leukemia (AML) with 4 out of 7 patients achieving composite Complete Remission (cCR) [1][3][4] - The company reported financial results for Q1 2025, showing a net loss of $14.1 million, with cash and cash equivalents of approximately $33.8 million as of March 31, 2025 [9][14] Clinical Data Highlights - SENTI-202 was well tolerated with no dose-limiting toxicities, and the preliminary recommended Phase 2 dose (RP2D) was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles [4] - All 4 patients who achieved cCR were measurable residual disease (MRD) negative, and responses have been maintained for follow-ups ranging from 4+ to 8+ months [1][4] - The ongoing enrollment in the Phase 1 study aims to confirm the RP2D and expand into disease-specific cohorts [1][3] Corporate Developments - The company is advancing its Logic-Gated cell therapy approach, which may have applications in both liquid and solid tumors, providing multiple pipeline expansion opportunities [1][2] - Senti Bio has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and increase market visibility [5] Financial Overview - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024, primarily due to higher external services costs [9][14] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024 [9][14] - The total operating expenses for the quarter were $16.4 million, slightly up from $16.3 million in the same period last year [9][14]

Core Insights - Senti Biosciences, Inc. presented positive preliminary data from the Phase 1 clinical trial of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3][5] - SENTI-202 is designed as a first-in-class off-the-shelf therapy that selectively targets CD33 and/or FLT3 antigens while sparing healthy cells, potentially widening the therapeutic window [5][6] - The company is currently enrolling adult patients with R/R CD33 and/or FLT3-expressing hematologic malignancies in the ongoing Phase 1 clinical trial [5] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][8] - The company's pipeline includes engineered cell therapies targeting challenging liquid and solid tumor indications, leveraging synthetic biology for enhanced precision and control [8] Industry Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [7] - Current treatment options for R/R AML are limited, with median overall survival typically around five months [7]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present new Phase 1 clinical data for its lead program, SENTI-202, at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 2025 [1][2] Company Overview - Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at challenging liquid and solid tumor indications, with SENTI-202 being a first-in-class off-the-shelf CAR NK cell therapy currently in Phase I clinical trials [3] Leadership and Communication - The upcoming conference call will be hosted by Timothy Lu, MD, PhD, CEO and Co-Founder, and Kanya Rajangam, MD, PhD, President and Chief Medical Officer [2] - Investors can access the conference call through a domestic and international dial-in number or via a webcast on the company's website, which will be archived for 90 days [2]